EGFR/TGFb fusion monoclonal antibody BCA101

{
  "id": "MLC-T-ONC-013285",
  "term": "EGFR/TGFb fusion monoclonal antibody BCA101",
  "field": "Oncology and biomedicine",
  "definition": "A bifunctional monoclonal antibody targeting both the receptor tyrosine kinase epidermal growth factor receptor (EGFR) and the pro-inflammatory cytokine human transforming growth factor beta (TGF-beta; TGFb), with potential antineoplastic activity. Upon administration of EGFR/TGFb fusion monoclonal antibody BCA101, the anti-EGFR moiety targets, binds to and prevents activation of EGFR-mediated signaling. This leads to an inhibition of EGFR-dependent downstream pathways and EGFR-dependent tumor cell proliferation and metastasis. The anti-TGFb moiety targets and binds to TGFb, thereby preventing the activation of TGFb-mediated signaling pathways. This may inhibit the proliferation of tumor cells in which TGFb is overactivated. EGFR and TGFb, mutated and/or overexpressed on the surfaces of various tumor cell types, play key roles in tumor cell proliferation and progression.",
  "synonyms": [
    "anti-EGFR/TGFb bispecific monoclonal antibody BCA101",
    "anti-EGFR/TGFb monoclonal antibody BCA101"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/egfr-tgfb-fusion-monoclonal-antibody-bca101/"
}